mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Clinical trial NCT02208375 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02208375
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

BRCA1 Mutation Carrier BRCA2 Mutation Carrier Endometrial Adenocarcinoma Estrogen Receptor Negative HER2/Neu Negative High Grade Ovarian Serous Adenocarcinoma Progesterone Receptor Negative Recurrent Breast Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Recurrent Uterine Corpus Carcinoma

Start date: 2014-11-11
Primary completion: 2028-06-30
Enrollment: 159

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.